Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR

The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show growing segments despite tariff-related challenges.

07/10/2026, 10:56 AM • GlobeNewswire

Intuitive Surgical's Moat Is Getting Stronger. Is This the Closest Thing to a 'Forever' Stock?

Intuitive Surgical maintains a dominant position in the robotic surgery market with its Da Vinci system, which benefits from strong competitive moats including surgeon training, high switching costs, and deep operating room integration. The company's recurring revenue model—driven primarily by accessories, instruments, and service contracts rather than system sales—supports steady earnings growth. Despite new competition from Medtronic's Hugo system, Intuitive Surgical's broad market presence and established leadership position its moat as increasingly stronger.

07/01/2026, 5:10 AM • The Motley Fool

Intuitive Surgical Stock Is Up Over 400%. Here's Why It's Still a No-Brainer Buy.

Intuitive Surgical, maker of the da Vinci surgical robot, has surged over 400% in the past decade despite currently trading 30% below all-time highs. The company's real growth driver is recurring revenue from services, instruments, and accessories rather than robot sales. With a current P/E of 49x (below its 5-year average of 69x), aggressive growth investors may view the pullback as a buying opportunity, though the stock remains volatile.

06/27/2026, 1:15 PM • The Motley Fool

This Healthcare Stock Trades at a Richer Valuation Than Nvidia. Could It Also Deliver Bigger Long-Term Returns?

While Nvidia leads the AI revolution with a 31x P/E ratio, Intuitive Surgical trades at 50x P/E but appears cheaper relative to its historical 70x average. The surgical robotics leader generates recurring revenue from parts and services (75% of revenue) supporting its da Vinci robots, offering more stable long-term growth than Nvidia's competitive chip market. With expanding FDA approvals for new applications, Intuitive Surgical presents a compelling growth opportunity for aggressive investors.

06/21/2026, 10:15 AM • The Motley Fool

Billionaire Ken Griffin Sold Amazon and Nvidia but Quietly Loaded Up on This Healthcare Giant

Ken Griffin's Citadel Advisors reduced positions in Nvidia and Amazon during Q1 while increasing its stake in Intuitive Surgical by 30.3%. Despite the medical device company facing headwinds from competition, lower margins on new products, and tariffs, analysts believe its strong competitive moat, large addressable market, and AI integration potential make it an attractive long-term investment at current valuations.

06/16/2026, 4:30 PM • The Motley Fool

3 Dividend Stocks to Hold for the Long Haul

The article recommends three healthcare dividend stocks for long-term investors: Bristol Myers Squibb, Merck, and Medtronic. Despite facing recent challenges like patent cliffs and competitive pressures, all three companies have strong dividend track records with consistent payout increases and promising pipelines to drive future growth.

06/16/2026, 6:15 AM • The Motley Fool

Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trials of AT7687, its lead GIPR antagonist candidate for obesity treatment.

06/09/2026, 7:00 AM • GlobeNewswire

Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?

Medtronic received FDA approval for its Hugo robotic-assisted surgery platform for urologic procedures in December 2025, marking its entry into a market dominated by Intuitive Surgical's da Vinci system. While Medtronic faces significant competitive headwinds due to Intuitive's 26-year head start, massive installed base of 11,395 systems, and broader procedure approvals, the robotic surgery market is projected to grow from $13.8 billion to $63.7 billion by 2035. Medtronic's Hugo is already approved in 35+ countries with procedure volumes growing 2-3x faster than the market, suggesting the company can grow alongside the expanding market without necessarily overtaking the leader.

06/08/2026, 7:21 AM • The Motley Fool

China's Puncture Robotics Firm True Health Files For Hong Kong IPO

Guangdong true Health Medical Technology, a Chinese medical robotics company specializing in puncture and ablation robots, has filed for a Hong Kong IPO to fund development and commercialization. While the company leads China's niche puncture robotics market with regulatory approvals, it faces significant challenges including minimal revenue (173,000 yuan in H1 2025), heavy dependence on a single customer for 90% of revenue, and substantial net losses (56.73 million yuan in H1 2025). The market for puncture robots is projected to grow significantly but remains in early stages.

06/05/2026, 8:55 AM • Benzinga

3 Beaten-Down Stocks to Buy and Hold Forever

Despite recent declines, three healthcare stocks—Intuitive Surgical, HCA Healthcare, and Abbott Laboratories—are positioned as long-term buy-and-hold opportunities. While facing macroeconomic headwinds and near-term challenges, each company has strong underlying fundamentals, innovative products, and exposure to growing healthcare trends that could drive significant long-term returns.

06/02/2026, 4:15 AM • The Motley Fool

A Rare Buying Opportunity May Be Here With This Top Stock

Intuitive Surgical's stock has declined approximately 30% since the start of 2026, presenting a potential buying opportunity for growth investors. Despite the stock decline, the company's da Vinci surgical robot system continues to show strong fundamentals with 12% year-over-year growth in installed systems and 17% growth in procedures performed. The company generates 75% of revenue from recurring parts and services, creating an annuity-like revenue stream. Historically, the stock has recovered from similar 30%+ declines eight times since its IPO.

05/31/2026, 8:15 AM • The Motley Fool

Wall Street Thinks Intuitive Surgical Stock Can Soar Over 30%. Here's Why Analysts are Right.

Intuitive Surgical stock has fallen 30% from early 2025 highs but Wall Street analysts maintain an average price target of $570, suggesting 30%+ upside potential. The surgical robotics leader's da Vinci system shows strong demand with 12% year-over-year growth in installed systems and 17% growth in surgeries performed. While the stock trades at a lofty 51x P/E ratio, analysts believe the company's recurring revenue from instruments, accessories, and services (75% of revenue) and long-term market opportunity justify recovery, supported by historical precedent of similar drawdowns followed by strong recoveries.

05/29/2026, 8:15 PM • The Motley Fool

A Once-in-a-Decade Opportunity: 1 Stock to Buy Hand Over Fist and Hold for Years

Medtronic is presented as an attractive investment opportunity for dividend, value, and growth investors. The stock has declined 40% from its 2021 peak, offering attractive valuations with a 3.7% dividend yield and 48 consecutive annual dividend increases. The company is ramping up its Hugo surgical robot to compete in the growing surgical robotics market, with potential for significant upside if the market recognizes its growth prospects.

05/17/2026, 8:15 AM • The Motley Fool

My Top 3 Healthcare Stocks for May 2026

The article recommends three healthcare stocks poised to benefit from rising federal healthcare spending projected to exceed $3 trillion within a decade. Pfizer offers an attractive 6.5% dividend yield with a robust drug pipeline; Intuitive Surgical dominates robotic surgery with recurring revenue from instruments and servicing; and Eli Lilly is capitalizing on blockbuster GLP-1 weight-loss drugs with strong revenue growth.

05/15/2026, 8:33 AM • The Motley Fool

Intuitive Surgical Has Dropped 20% This Year. Wall Street Says It's Time to Buy.

Intuitive Surgical's stock has fallen 20% in 2026, entering its own bear market. Despite the decline, two-thirds of analysts rate it a buy with a 33% upside price target. The company continues rapid growth with 12% year-over-year increases in da Vinci system installations. However, the stock remains richly valued at 52x P/E ratio and highly volatile, making it suitable only for aggressive growth investors with long-term commitment.

05/14/2026, 4:15 PM • The Motley Fool